Table 2.
Safety profile of temsirolimus.
| Trial | Metabolic adverse events |
Cutaneomucous |
Hematologic adverse events |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypertryglyceridemia/hypercholesterolemia |
Hyperglycemia |
Rash |
Mucositis |
Anémia |
Thrombopenia |
Leucopenia |
Pneumonitis |
|||||||||
| Any grade | Grade 3–4 | Any grade | Grade 3–4 | Any grade | Grade 3–4 | Any grade | Grade 3–4 | Any grade | Grade 3–4 | Any grade | Grade 3–4 | Any grade | Grade 3–4 | Any grade | Grade 3–4 | |
| Raymond et al25 | 42% | 34% | ND | ND | 75% | 4% | 75% | 4% | ND | ND | 29% | 8% | ND | ND | ND | ND |
| Motzer et al35 | 32% | 15% | ND | ND | 48% | 6% | ND | ND | ND | ND | 35% | 7% | 37% | 32% | ND | ND |
| Atkins et al27 | 28% | 6% | 20% | 17% | 76% | <5% | 70% | <5% | 29% | 9% | 25% | <5% | ND | ND | 5.4% | 1.8% |
| Hudes et al34 | 27% | 3% | 26% | 11% | 47% | 4% | 20% | 1% | 45% | 20% | 14% | 1% | 6% | 1% | 4% | 1% |
| Trial | Pneumonitis | |
|---|---|---|
| Any grade | Grade 3–4 | |
| Raymond et al25 | ND | ND |
| Motzer et al35 | ND | ND |
| Atkins et al27 | 5.4% | 1.8% |
| Hudes et al34 | 4% | 1% |
Abbreviation: ND, not determined.